Bioretec: RemeOs screw secures additional US reimbursement
Summary
- CMS confirmed Transitional Pass-Through Payment status for Bioretec’s RemeOs trauma screw in its final decision for 2027. The reimbursement provides hospitals with a separate payment for the device on top of the standard procedure payment.
- The analyst says the reimbursement’s continuation was in line with expectations, so estimates are unchanged. The status remains valid until September 2028 and may help ease adoption by reducing the impact of the implant’s higher purchase price.
- The analyst identifies US sales growth for the RemeOs screw as Bioretec’s most important short-term value driver. The company still needs to persuade local surgeons and hospital purchasing committees of the product’s benefits.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 11/10/2026 at 8:25 am EET.
On Monday, Bioretec announced that the US Centers for Medicare & Medicaid Services (CMS) has confirmed Transitional Pass-Through Payment (TPT) status for the RemeOs trauma screw in its final decision for 2027. TPT status lowers the threshold for hospitals to adopt the product. As the reimbursement has been in effect since October 2025 and its continuation was in line with our expectations, the news prompts no changes to our estimates.
TPT reimbursement gives hospitals a separate payment for new-technology devices on top of the standard procedure payment. This is critically important for Bioretec, as the higher purchase price of the new absorbable metal implant could otherwise become a barrier to its broader adoption in the US. The reimbursement status is valid until September 2028, giving the company an important window of opportunity to establish the product in the market. We have previously identified the US sales ramp-up of the RemeOs screw as Bioretec’s most important short-term value driver. Although the regulatory reimbursement decisions are now clear, the company still needs to convince local surgeons and hospital purchasing committees of the product’s benefits.